CAESAR Trial (Cardiac And ESophageal cA Response to chemoradiotherapy)

Summary

Chemotherapy and radiation therapy is a standard treatment for advanced stage esophageal cancer. These treatments are effective in treating esophageal cancer. But they can also cause side effects. One common side effect is heart disease in approximately one in ten patients.

The goal of this study is to observe the changes in the esophageal tumor and heart during cancer treatment. We plan to do MRIs, bloodwork and surveys three times. These test will be before cancer treatment begins, during cancer treatment and after cancer treatment with chemotherapy and radiation therapy.

Using these tests, we hope to see which patients are more likely to have a successful treatment of their cancer. We hope to see if there are any early signs of heart damage. We also hope to see whether these added test are tolerable.

This study will not alter your cancer care. But it will help inform us on how your tumor responds to our treatment. The information from this trial may help patients like yourself in the future.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 110

Inclusion criteria:

1. Stage II/III esophageal squamous cell carcinoma or adenocarcinoma confirmed by biopsy.

2. Patient undergoing chemotherapy and radiation therapy at the same time with the goal of curing the cancer.

3. Patients who are able to care for themselves at home.

4. Age > 18 years

5. Female patients of childbearing age must have a negative pregnancy test within 21 days before the start cancer treatment. They must agree to use adequate birth control if conception is possible during the study and up to 6 months after the surgery.

6. Patient must be able and willing to follow study instructions.

7. Patient able to understand and willing to consent to the study.

Exclusion criteria:

1. Patient is unable to undergo MRIs.

2. Pregnant women.

3. Patients with kidney failure.

4. Patients who were treated with radiation therapy to the chest or upper abdomen in the past.

5. Patients with a history of heart disease.

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

Sandra Rivest Registered Nurse DIAGNOSTIC IMAGING

Principal investigator:

Sangjune Lee

Clinical trial:

No

REB-ID:

HREBA.CC-21-0031